Basal insulin only — Competitive Intelligence Brief

Basal insulin only (Basal insulin only) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin (basal/long-acting). Area: Diabetes.

phase 3 Insulin (basal/long-acting) Insulin receptor Diabetes Small molecule

Target snapshot

Basal insulin only (Basal insulin only) — Mount Sinai Hospital, Canada. Basal insulin provides a steady, long-acting background level of insulin to regulate fasting blood glucose and suppress hepatic glucose production.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Basal insulin only TARGET	Basal insulin only	Mount Sinai Hospital, Canada	phase 3	Insulin (basal/long-acting)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin (basal/long-acting) class)

1. Mount Sinai Hospital, Canada · 1 drug in this class